Cargando…

Upregulation of miR-142 in papillary thyroid carcinoma tissues: a report based on in silico and in vitro analysis

Papillary thyroid carcinoma (PTC) accounts for approximately 80% of all human thyroid malignancies. Recently, there has been a dramatic rise in the prevalence of thyroid cancer all over the globe. Through analysis of the GEO database, GSE104005, the authors of the current research were able to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: Valizadeh, Sepehr, Zehtabi, Mojtaba, Feiziordaklou, Neda, Akbarpour, Zahra, Khamaneh, Amir Mahdi, Raeisi, Mortaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shiraz University 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661674/
https://www.ncbi.nlm.nih.gov/pubmed/36718241
http://dx.doi.org/10.22099/mbrc.2022.43947.1757
Descripción
Sumario:Papillary thyroid carcinoma (PTC) accounts for approximately 80% of all human thyroid malignancies. Recently, there has been a dramatic rise in the prevalence of thyroid cancer all over the globe. Through analysis of the GEO database, GSE104005, the authors of the current research were able to determine the differential expression of microRNAs (DEMs) as well as their target genes. Real-time PCR was used on a total of 40 samples, 40 of which were from PTC samples and 40 from normal tissues, in order to validate the discovered DEMs and the genes. Gene Ontology (GO) categories were identified, and KEGG was used to conduct pathway enrichment analysis. The multiMiR R package was used to predict target genes of DEMs. Mir-142 was found to be overexpressed in PTC samples, as compared to normal tissues, and this was validated by the identification and validation. In addition, metal ion binding and the cellular response to metal ions were identified as essential pathways in the carcinogenesis of PTC. This demonstrates their significance in the development of this malignancy. The results of our research will serve as the foundation for further research in the area of miRNA-based cancer treatment.